Coupling Reactions of R-(N-Carbamoyl)alkylcuprates
NMR (CDCl3, TMS) δ 14.3, 22.0, 22.3, 24.2, 24.6 (25.0), 25.4
(25.8), 26.4, 28.4, 32.4, 45.6 (45.9), 47.5 (48.0), 59.6 (60.0), 78.9,
124.5, 150.0, 154.5, 168.6 (rotamer); HR MS (FAB, m/z)
324.2177 (MH+) (Calcd for M+ + H, C18H30NO4, 324.2175).
1-P h en ylm eth yl-5-car boeth oxy-4-[1-(1,1-dim eth yleth yl-
oxyca r b on yl)p yr r olid in -2-yl]-1,2,3,6-t e t r a h yd r op yr i-
TMS) δ 1.27 (t, J ) 7.2 Hz, 3 H), 1.35 (s, 9 H), 1.45 (s, 5 H),
1.46-1.62 (m, 3 H), 1.62-1.85 (m, 3 H), 1.85-2.25 (m, 4 H),
2.25-2.55 (m, 1 H), 2.75-2.95 (m, 1 H), 3.34 (dt, J ) 18.9 Hz,
J ) 6.0 Hz, 1 H), 4.00-4.30 (m, 2 H), 5.15.(dd J ) 4.5, J )
12.0 Hz), 5.36 (dd J ) 4.5 Hz, J ) 12.0 Hz, 1 H, rotamer); 13
C
NMR (CDCl3, TMS) δ 14.2, 22.0, 22.2, 24.4 (24.9), 26.7 (27.0),
27.4, 28.3 (28.5), 29.3 (29.4), 30.7 (30.9), 32.5 (32.7), 44.1 (44.9),
46.5 (46.9), (59.1) 59.9, 79.1, 123.4, 152.3, 156.1, 168.1 (rota-
mer); HR MS (FAB, m/z) 352.2491 (MH+) (Calcd for M+ + H,
1
d in e (5). H NMR (CDCl3, TMS) δ 1.25 (t, J ) 6.8 Hz, 3 H),
1.39 (1.48) (s, 9 H, rotamer), 1.55-2.65 (m, 8 H), 3.10-3.40
(m, 3 H), 3.40-3.75 (m, 3 H), 4.15 (q, J ) 6.9 Hz, 2 H), 5.20 (t,
J ) 7.2 Hz), 5.25-5.55 (2 br s, 1 H, rotamer), 7.32 (s, 5 H); 13
C
C
20H34NO4, 352.2488).
NMR (CDCl3, TMS) δ 13.8, 23.8, 24.6, 28.0, 31.7 (32.1), 46.9,
48.3, 52.8, 58.7, 59.6, 61.6, 78.7, 122.3, 126.6, 127.8, 128.3
(128.7), 137.8, 150.8, 153.9, 166.0 (rotamer); HR MS (FAB, m/z)
415.2600 (MH+) (Calcd for M+ + H, C24H35N2O4, 415.2595).
1-P h en ylm eth yl-4-car boeth oxy-3-[1-(1,1-dim eth yleth yl-
oxyca r b on yl)p yr r olid in -2-yl]-1,2,5,6-t e t r a h yd r op yr i-
1,1-Dim eth yleth yl Ester (2-Ca r boeth oxy-1-cycloh exen -
1-ylm et h yl)m et h ylca r b a m ic Acid (10). 1H NMR (CDCl3,
TMS) δ 1.29 (t, J ) 7.2 Hz, 3 H), 1.45 (s, 9 H), 1.50-1.80 (m,
4 H), 2.03 (br s, 2 H), 2.29 (br s, 2 H), 2.74 (br s, 3 H), 4.18 (q,
J ) 7.2 Hz, 4 H); 13C NMR δ (CDCl3, TMS) 14.2, 21.8, 22.1,
26.8, (28.1) 28.4, 32.5, 49.7, 50.7, 60.3, 79.5, 127.8, 143.6, 156.0,
168.8 (rotamer); HR MS (FAB, m/z) 298.2014 (MH+) (Calcd
for M+ + H, C16H28NO4, 298.2018).
1
d in e (6). H NMR (CDCl3, TMS) δ 1.26 (t, J ) 6.9 Hz, 3 H),
1.38 (1.46) (s, 9 H, rotamer), 1.55-2.20 (m, 5 H), 2.20-3.40
(m, 6 H), 3.40-3.80 (m, 3 H), 4.16 (q, J ) 7.2 Hz, 2 H), 5.12 (t,
Bis(1,1-d im eth yleth yl) Ester [2,2′-Bip yr r olid in e]-1,1′-
d ica r boxylic Acid (11). 1H NMR δ (CDCl3 at 7.24 ppm as
internal standard) 1.44 (s, 18 H), 1.53-2.18 (br m, 8 H), 3.08-
J ) 7.4 Hz), 5.20-5.60 (3 br s, 1 H, rotamer), 7.30 (s, 5 H); 13
C
NMR (CDCl3, TMS) δ 14.2, 24.2, 26.7, 28.4, 32.4 (32.6), 47.4,
49.1, 52.4 (53.0), 58.5, 60.1, (62.1) 62.3, 79.3 (81.7), 122.4,
127.1, 128.2, 129.0, 137.8, 149.8, 154.4, 167.2 (rotamer); HR
MS (FAB, m/z) 415.2600 (MH+) (Calcd for M+ + H, C24H35N2O4,
415.2595).
3.41 (m, 4 H), 3.41-3.61 (br s, 1 H), 3.61-3.95 (br s, 1 H); 13
C
NMR δ (CDCl3 at 77.0 ppm as internal standard) 22.7, 23.4,
28.5, 46.6 (45.9, rotamer), 59.7, 79.5 (78.5, rotamer), 155.2; HR
MS (FAB, m/z) 341.2441 (MH+) (Calcd for M+ + H, C18H33N2O4,
341.2440).
1,1-Dim et h ylet h yl 3-Ca r b oet h oxy-2-[1-(1,1-d im et h yl-
ethyloxycarbonyl)pyrrolidin-2-yl]-1,4,5,6-tetrahydropyridine-
1,2,3,6,7,8,9,9b-Octa h yd r o-5H-p yr r olo[2,1-a ]isoin d ole-
5-on e (13). 1H NMR δ (CDCl3, TMS) 1.00-1.20 (m, 1 H), 1.50-
1.80 (m, 4 H), 1.95-2.10 (m, 1 H), 2.10-2.20 (m, 3 H), 2.20-
2.40 (m, 3 H), 3.15-3.30 (m, 1 H), 3.30-3.50 (m, 1 H), 3.95-
4.05 (m, 1H); 13C NMR δ (CDCl3, TMS) 20.7, 22.3, 22.5, 24.4,
28.9, 29.7, 42.4, 68.1, 132.5, 157.4, 177.3; HR MS (FAB, m/z)
178.1233 (MH+) (Calcd for M+ + H, C11H16NO, 178.1232).
1
1-ca r boxyla te (7). H NMR (CDCl3, TMS) δ 1.25 (t, J ) 7.1
Hz, 3 H), 1.43 (s, 9 H), 1.47 (s, 9 H), 1.60-2.05 (m, 5 H), 2.05-
2.70 (m, 4 H), 2.95-3.15 (m, 1 H), 3.15-4.00 (m, 2 H), 4.15 (q,
J ) 7.2 Hz, 2 H), 5.22 (t, J ) 8.6 Hz, 1 H); 13C NMR (CDCl3,
TMS) δ 14.2, (23.8) 24.3, 24.8, 28.3, 28.5, 31.1, 32.5, 45.1, 45.8,
47.9 (48.0), 59.6 (60.1), 78.6 (78.9), 80.9 (81.2), 118.0, 153.3,
153.7, (154.4) 154.9, 167.1 (rotamer); LC-MS (EI, m/z) 6.01
min, 425.1 (M+ + 1, 30%), 369.1 (20%), 325.1 (60%), 269.1
(100%), 225.1 (70%), 179.1 (90%).
Ack n ow led gm en t. S. Li gratefully acknowledges
Schering-Plough Research Institute (SPRI) and its
employee education assistance program. The guidance
of Drs. William J . Greenlee, Michael Czarniecki, and
J ohn W. Clader at Schering-Plough Research Institute
is gratefully appreciated.
1,1-Dim eth yleth yl 2-(2-Ca r boeth oxy-1-cycloh exen -1-
1
yl)-1-p ip er id in eca r boxyla te (8). H NMR (CDCl3, TMS) δ
1.26 (t, J ) 6.9 Hz, 3 H), 1.38 (s, 9 H,), 1.40-1.75 (m, 9 H),
1.75-1.85 (m, 1 H), 2.00-2.30 (m, 3 H), 2.30-2.50 (m, 1 H),
3.00 (m, 1 H), 3.96 (dd, J ) 6.3 Hz, J ) 12.0 Hz, 1 H), 4.13 (q,
J ) 6.6 Hz, 2 H), 5.07 (t, J ) 5.1 Hz, 1 H); 13C NMR (CDCl3,
TMS) δ 14.2, 19.2, 22.1, 22.2, 22.8, 25.6, 26.7, 27.3, 28.3, 39.7,
55.3, 59.9, 79.2, 123.8, 151.5, 155.8, 168.5; HR MS (FAB, m/z)
338.2330 (MH+) (Calcd for M+ + H, C19H32NO4, 338.2331).
1,1-Dim eth yleth yl 2-(2-Ca r boeth oxy-1-cycloh exen -1-
yl)h exa h yd r o-a zep in e-1-ca r boxyla te (9). 1H NMR (CDCl3,
Su p p or t in g In for m a t ion Ava ila b le: 1H and 13C NMR
spectra for compounds 4-11 and 13. This material is available
J O026375F
J . Org. Chem, Vol. 68, No. 3, 2003 973